Failure analysis of clinical trials to test the amyloid hypothesis

Annals of Neurology

Volumn 76, Issue 2, 2014, Pages 159-161

  Hyman, Bradley T ^a   Sorger, Peter ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID;

ALZHEIMER DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DATA ANALYSIS; HUMAN; HYPOTHESIS; NOTE; PRIORITY JOURNAL; STUDY DESIGN; DRUG DEVELOPMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PLAQUE, AMYLOID; STANDARDS;

ALZHEIMER DISEASE; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG DISCOVERY; HUMANS; PLAQUE, AMYLOID;

EID: 84907597135     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24227     Document Type: Note

References (15)

1. Hardy J, Selkoe DJ,. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-356.
2. Holtzman DM, Herz J, Bu G,. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2: a006312.
3. Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012; 488: 96-99.
4. Karran E, Mercken M, De Strooper B,. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011; 10: 698-712.
5. Oyama F, Cairns NJ, Shimada H, et al. Down's syndrome: up-regulation of beta-amyloid protein precursor and tau mRNAs and their defective coordination. J Neurochem 1994; 62: 1062-1066.
6. Rovelet-Lecrux A, Hannequin D, Raux G, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006; 38: 24-26.
7. Tanzi RE,. The genetics of Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2 (10).
8. Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 2012; 71: 362-381.
9. Serrano-Pozo A, Qian J, Monsell SE, et al. Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. J Neuropathol Exp Neurol 2013; 72: 1182-1192.
10. Karran E, Hardy J,. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol 2014; 76: 185-205.
11. Toyn JH, Ahlijanian M,. Interpreting Alzheimer's disease clinical trials in light of the effects on amyloid-β. Alzheimer Res Ther 2014; 6: 14.
12. Hyman BT,. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol 2011; 68: 1062-1064.
13. Serrano-Pozo A, Qian J, Monsell SE, et al. Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Ann Neurol 2014; 75: 597-601.
14. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367: 795-804.
15. Mullard A,. Sting of Alzheimer's failures offset by upcoming prevention trials. Nat Rev Drug Discov 2012; 11: 657-660.